{"filings":[{"id":1922569,"accession_number":"0001171843-26-004974","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2026-07-29T11:00:20+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva Q2 revenues $4.1B, GAAP loss $0.49/share; raises 2026 outlook for key innovative brands","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenues $4.1B (-1% YoY); GAAP loss per share $0.49; non-GAAP diluted EPS $0.02 (includes $0.61 Emalex impact).","Key innovative brands (AUSTEDO, AJOVY, UZEDY) grew 43% YoY LC to >$1B; 2026 revenue outlook raised to ~$3.7B combined.","Acquired Emalex for ~$700M cash; NDA for ecopipam (Tourette) submitted; $726M expenses in Q2.","Generics revenues down 15% YoY LC due to lenalidomide competition; biosimilars on track for $800M by 2027.","ADS program replaced with ordinary shares on NYSE starting Sept 14, 2026; Fitch upgraded to BBB-."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":721798,"accession_number":"0001193125-26-245203","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2026-05-28T20:05:43+00:00","items":["5.07"],"status":"ready","headline":"Teva shareholders re-elect Sol J. Barer to board, approve advisory pay vote","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Dr. Sol J. Barer elected to board with 627.8M for, 245.9M against, 0.5M abstain (broker non-votes 50.7M).","Non-binding advisory compensation proposal passed with 796.0M for, 77.1M against, 1.2M abstain.","Kesselman & Kesselman (PwC) ratified as independent auditor for 2027 with 880.5M for, 36.1M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99041,"accession_number":"0001171843-26-002796","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Teva Q1 revenues $4.0B (+2% YoY); AUSTEDO up 41%; to acquire Emalex for $700M cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q1 GAAP diluted EPS $0.31; Non-GAAP diluted EPS $0.53; revenues $3,982M (+2% USD, -3% LC).","Key innovative brands: AUSTEDO $578M (+41% YoY), AJOVY $196M (+35%), UZEDY $63M (+62%).","Generics down 16% LC due to lenalidomide competition and Japan BV divestiture.","Acquired Emalex Biosciences for $700M upfront + up to $200M milestones + royalties; ecopipam (Tourette) NDA-ready; close expected Q3 2026.","2026 outlook maintained; Non-GAAP diluted EPS $1.91-$2.11 (stand-alone $2.57-$2.77)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114838,"accession_number":"0001171843-26-000462","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva posts FY 2025 revenue $17.3B (+4% YoY), non-GAAP EPS $2.93, guides FY26 rev $16.4-16.8B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2025 revenues $17.3B (+4% YoY); GAAP diluted EPS $1.21, non-GAAP diluted EPS $2.93.","Key innovative brands AUSTEDO ($2.26B, +34% YoY), AJOVY ($673M, +30%), UZEDY ($191M, +63%) drove 35% YoY growth.","Non-GAAP operating income margin 28.4% (vs 26.2% in 2024); free cash flow $2,396M.","Gross debt reduced to $16.8B, net debt to $13.3B; credit ratings upgraded by three agencies in 2025.","2026 outlook: revenues $16.4-16.8B, non-GAAP diluted EPS $2.57-2.77, free cash flow $2.0-2.4B."],"consensus_eps_estimate":null,"consensus_eps_actual":1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":1500000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114837,"accession_number":"0001171843-26-000174","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva pre-announces 2025 revenue $16.8-$17.0B, raises guidance; projects 2030 mid-single-digit CAGR","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Expected 2025 revenue $16.8-$17.0B (low end), adjusted EBITDA $4.8-$5.0B (midpoint).","Diluted EPS $2.55-$2.65 (higher end); free cash flow $1.6-$1.9B (higher end).","Duvakitug milestones expected to add $500M revenue and ~$400-430M adjusted EBITDA.","2027 targets: low-single-digit revenue growth, 30% operating margin, FCF >$2.7B, net leverage <2x.","2030 targets: mid-single-digit CAGR, >30% operating margin, FCF >$3.5B, cumulative savings $700M."],"consensus_eps_estimate":null,"consensus_eps_actual":1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":1500000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131224,"accession_number":"0001193125-25-316063","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Teva extends revolving credit facility maturity to April 2028, adjusts leverage covenants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maturity extended from April 2027 to April 2028 via second one-year extension of the revolving facility.","Maximum leverage ratio set at 4.25x for Q4 2025 and thereafter; can increase 0.5x for acquisitions over $250M.","Covenants suspended if Teva achieves Investment Grade Status (Baa3/BBB- from two agencies); reinstated on loss or default.","Consent fee of 0.08% of total commitments paid to lenders approving the amendment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131223,"accession_number":"0001171843-25-007000","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva Q3 2025: revenue $4.48B (+3%), non-GAAP EPS $0.78; Austedo outlook raised; TAPI sale restart","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.48B (+3% YoY); GAAP EPS $0.37, non-GAAP EPS $0.78 (vs $0.69 YoY).","Austedo revenue $618M (+38% YoY); 2025 outlook raised to $2.05B-$2.15B (from $1.95B-$2.05B).","Non-GAAP operating margin 28.9% (+86 bps YoY); on track for 30% target by 2027.","Exclusive TAPI sale discussions terminated; renewed sales process initiated; divestiture intent maintained.","Full-year 2025 non-GAAP EPS guidance raised to $2.55-$2.65 (midpoint +$0.025); FCF unchanged $1.6B-$1.9B."],"consensus_eps_estimate":null,"consensus_eps_actual":0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":12547000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147813,"accession_number":"0001171843-25-004808","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva Q2 2025 Non-GAAP EPS $0.66 (+9% YoY); Raises 2025 Innovative Product Revenue Outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenues $4.176B flat YoY; GAAP EPS $0.24; Non-GAAP EPS $0.66 (up from $0.61).","AUSTEDO global revs $498M (+19% LC), AJOVY $155M (+31% LC), UZEDY $54M (+120% YoY).","Raised 2025 revenue outlook: AUSTEDO $2,000-2,050M, AJOVY $630-640M, UZEDY $190-200M.","Non-GAAP operating margin 27.1% (vs 25.3% Q2 2024); adjusted EBITDA $1,233M (+6%).","Free cash flow $476M (+47% YoY); on track for $700M net savings by 2027 from Transformation programs."],"consensus_eps_estimate":null,"consensus_eps_actual":0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":8067000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166515,"accession_number":"0001193125-25-135942","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Teva shareholders elect board, approve executive compensation and auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Chen Lichtenstein elected to board until 2027; Amir Elstein, Roberto Mignone, Perry Nisen, Tal Zaks elected until 2028.","Non-binding advisory vote on executive compensation approved with 688.8M for vs 99.2M against.","Amended compensation policy for executives and directors approved with 710.2M for.","Reappointment of Kesselman & Kesselman (PwC) as auditor approved with 820.2M for.","All proposals passed with substantial majorities; no material dissent reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166514,"accession_number":"0001193125-25-129488","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Teva issues €1B and $1.2B in senior notes to refinance debt, upsizes tender offer to $2.25B","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["€1B of 4.125% Senior Notes due 2031; $500M of 6.000% notes due 2032; $700M of 5.750% notes due 2030.","Net proceeds fund tender offer for up to $2.25B (upsized from $2B) and repay other outstanding debt.","Notes are senior unsecured obligations guaranteed by Teva; customary covenants and events of default.","Issuance made under Teva's existing shelf registration statement filed February 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166513,"accession_number":"0001193125-25-125071","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Teva prices $2.3B multi-tranche senior notes offering to refinance existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Upsized offering from $2B to ~$2.3B equivalent across three tranches.","€1B 4.125% due 2031 (priced 99.349%), $500M 6.000% due 2032 (99.256%), $700M 5.750% due 2030 (99.418%).","Settlement expected May 28, 2025, subject to customary closing conditions.","Proceeds to fund tender offers for existing notes with coupons 3.15%-8.125% maturing 2026-2031.","Net proceeds may also be used for debt repayment at maturity, tender, or redemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166512,"accession_number":"0001171843-25-002849","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva Q1 2025: revenue $3.9B (+5% LC), Non-GAAP EPS $0.52 (+8% YoY); raises FY outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $3.9B (+5% local currency, +2% reported); GAAP EPS $0.18, Non-GAAP EPS $0.52 (vs $0.48 YoY).","Key innovative products grew ~39% YoY: AUSTEDO $411M (+39%), AJOVY $139M (+26%), UZEDY $39M.","FY2025 guidance raised: Non-GAAP EPS $2.45-$2.65 (midpoint +$0.10), Non-GAAP op income $4.3-$4.6B (+$200M at low end).","Generics grew in all regions (U.S. +5%, Europe +1%, Intl +2% in local currency).","On track for 30% operating margin by 2027; announces $700M net savings program."],"consensus_eps_estimate":null,"consensus_eps_actual":0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":3891000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183938,"accession_number":"0001171843-25-000493","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva FY2024 revenue $16.5B, GAAP EPS loss $1.45; non-GAAP EPS $2.49; sees 2025 rev $16.8-17.4B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 revenues $16.5B, +4% USD (+6% local currency); GAAP net loss $1.639B ($1.45/share) vs $559M loss in FY2023.","Non-GAAP diluted EPS $2.49, down from $2.56; adjusted EBITDA $4.78B.","Key product revenues: AUSTEDO >$1.6B, AJOVY $507M (+18% local), UZEDY $117M.","Generics grew 15% in U.S., 6% in Europe, 15% in International Markets (local currency).","FY2025 outlook: revenue $16.8-$17.4B, non-GAAP EPS $2.35-$2.65, free cash flow $1.6-$1.9B."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":16544000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200533,"accession_number":"0001193125-24-256014","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Teva elects Chen Lichtenstein to board effective Dec 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chen Lichtenstein elected as independent director, effective Dec 1, 2024, until 2025 annual meeting.","Lichtenstein was CFO of Syngenta Group (2020-2023) and previously CEO of ADAMA Ltd.","He holds a Ph.D. in Business Administration from Stanford and multiple degrees from Hebrew University.","Compensation will be the same as Teva's other non-executive directors.","No material related-party transactions or family relationships with Teva executives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200532,"accession_number":"0001171843-24-006034","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva Q3 rev $4.3B (+13% YoY); raises FY2024 guidance; Austedo $435M (+28%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenues $4.3B (+13% USD, +15% local currency); Non-GAAP diluted EPS $0.69 vs $0.60 YoY.","Austedo US revs $435M (+28%); AJOVY global $137M (+21% local); Uzedy US $35M, FY outlook raised to ~$100M.","Generics up 30% US, 8% Europe, 13% Int’l Markets (local currency); biosimilar to Prolia accepted by FDA/EMA.","FY2024 guidance raised: rev $16.1-16.5B, Adj EBITDA $4.7-5.0B, Non-GAAP EPS $2.40-2.50.","GAAP net loss $437M from $600M goodwill impairment and $450M legal provisions; cash from ops $693M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":12315000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216547,"accession_number":"0001171843-24-004270","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva Q2 revenue $4.2B +7%, non-GAAP EPS $0.61, raises full-year 2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $4.2B (+7% USD, +11% local currency); GAAP loss $0.75/share, non-GAAP EPS $0.61.","Generics grew 16% US, 8% Europe, 22% International; AUSTEDO US revenue $407M (+32%).","Raised 2024 guidance: revenue $16.0-16.4B, non-GAAP EPS $2.30-2.50, adj. EBITDA $4.6-5.0B.","Pipeline: duvakitug top-line now Q4 2024; olanzapine LAI positive Phase 3; SIMLANDI launch.","Free cash flow $324M; $506M tax hit from Israeli Tax Authority settlement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":7983000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236198,"accession_number":"0001193125-24-167489","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Teva settles Israeli tax dispute for ~$750M over 2008-2020, plus up to $500M contingent","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Teva to pay ~$750M to Israeli Tax Authorities over 2024-2029 for tax years 2008-2020.","Includes ~$500M corporate taxes on previously tax-exempt earnings under Encouragement for Capital Investment Law.","Additional ~$250M for other disputed tax issues in the same period.","Contingent payment of 5%-7% of future dividends/repurchases, capped at ~$500M.","Settlement ends litigation with ITA over historical tax years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236197,"accession_number":"0001193125-24-156043","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Teva shareholders elect four directors, approve say-on-pay and auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Prof. Varda Shalev to board through 2026; Rosemary Crane, Gerald Lieberman, Prof. Ronit Satchi-Fainaro through 2027.","Non-binding advisory vote on executive compensation approved: 571,822,049 for vs 120,609,632 against.","Shareholders recommended annual advisory vote on exec comp (one-year frequency) with 536,980,720 votes.","Ratification of Kesselman & Kesselman (PwC) as independent auditor approved: 731,150,255 for, 30,335,560 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236196,"accession_number":"0001193125-24-138936","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Teva appoints Matthew Shields as EVP Global Operations; Eric Drapé departs after 11 years","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Matthew Shields becomes EVP Global Operations effective June 3, 2024, based in Parsippany, NJ.","Shields previously SVP Manufacturing at Merck Animal Health; prior roles at Sanofi and Amgen.","Initial base salary of $825,000 with 100% target annual cash incentive, equity awards, and $200,000 sign-on cash.","Eric Drapé leaves Teva after 11 years, including over 4 years as EVP Global Operations.","Shields reports directly to CEO Richard Francis as part of the Pivot to Growth strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236195,"accession_number":"0001193125-24-133759","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva Q1 revenue $3.8B (+4% YoY), non-GAAP EPS $0.48, reaffirms FY24 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.819B (+4% YoY, +5% local currency); generics up 9% globally.","AUSTEDO U.S. sales up 67% YoY; AJOVY $113M (+18% YoY).","Non-GAAP diluted EPS $0.48 (vs $0.40); GAAP loss per share $0.12 (vs $0.20 loss).","FY2024 guidance reaffirmed: revenue $15.7-16.3B, non-GAAP EPS $2.20-2.50, free cash flow $1.7-2.0B.","Positive Phase 3 efficacy results for olanzapine LAI (TEV-749) for schizophrenia; no PDSS observed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":3819000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236194,"accession_number":"0001193125-24-100771","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2024-04-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Teva realigns reporting segments; Canada moved to International Markets from North America","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Canada will be reported as part of International Markets segment, not North America, effective Q1 2024.","Recast 2023 and 2022 segment data shows US segment revenue $7,731M (2023) and segment profit $2,394M.","Canada 2023 revenue $393M, down 12.5% from $449M in 2022, included in International Markets.","No impact on previously reported consolidated financial statements; prior periods restated for comparability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253895,"accession_number":"0001157523-24-000137","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2024-01-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva FY2023 revenue $15.8B, Non-GAAP EPS $2.56; AUSTEDO $1.2B; 2024 guidance issued; revises prior results","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2023 revenues $15,846M, up 7% in local currency; Q4 revenues $4,465M.","Non-GAAP diluted EPS $2.56 (vs $2.52 in 2022); GAAP net loss $(0.50) per share.","AUSTEDO annual revenue exceeded $1.2B (+28%); AJOVY $435M (+16%).","2024 outlook: revenue $15.7-$16.3B, Non-GAAP EPS $2.20-$2.50, free cash flow $1.7-$2.0B.","Revision: $132M contingent consideration understatement; material weakness in internal controls identified."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":15846000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271342,"accession_number":"0001157523-23-001677","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva Q3 revenue up 7% to $3.9B, raises FY revenue guidance to $15.1-$15.5B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.85B (+7% YoY); GAAP EPS $0.07, non-GAAP EPS $0.60.","Raised 2023 revenue outlook to $15.1-$15.5B from $15.0-$15.4B; reaffirms non-GAAP EPS $2.25-$2.55.","AUSTEDO and AJOVY drove growth; global generics revenues increased across all segments.","Entered exclusive collaboration with Sanofi on Anti TL1-A (TEV-'574) in October 2023.","Appointed Dr. R. Ananthanarayanan as CEO of Teva api; olanzapine LAI Phase 3 results now H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":11389000000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271341,"accession_number":"0001193125-23-250305","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2023-10-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Teva and Sanofi partner on anti-TL1A therapy TEV-574 for IBD; $500M upfront","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Teva receives €469M ($500M) upfront and up to €940M ($1B) in development/launch milestones.","Companies share development costs equally and split net profits/losses in major markets.","Sanofi leads Phase 3 program; Teva commercializes in Europe/Israel, Sanofi in North America/Asia.","TEV-574 is in Phase 2b for ulcerative colitis and Crohn's disease; initial data expected in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288207,"accession_number":"0001193125-23-245614","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2023-09-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Teva appoints Christine Fox as EVP U.S. Commercial; Sven Dethlefs departing Nov 17","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sven Dethlefs, EVP North America Commercial, to leave Teva on November 17, 2023 after 15 years.","Christine Fox appointed EVP U.S. Commercial; previously Global President, Gene Therapies at Novartis.","Fox brings 30+ years industry experience from Novartis, Amgen, Merck, Takeda.","CEO Richard Francis thanked Dethlefs and expressed confidence in Fox's ability to lead U.S. business."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288206,"accession_number":"0001193125-23-219539","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2023-08-24T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Teva settles DOJ price-fixing charges with $225M fine, DPA; avoids federal exclusion","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Teva enters Deferred Prosecution Agreement with DOJ over 2020 price-fixing charges for generic drugs.","Fine of $225M payable over 5 years: $22.5M/yr 2024-2027, $135M in 2028.","Teva to donate $50M of two generic products (at wholesale cost) and divest one generic product.","Admits a single former employee engaged in three instances of collusion with competitors (2013-2015).","DPA term is 3 years; upon compliance and payment, charges dismissed with prejudice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288205,"accession_number":"0001193125-23-201735","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Teva elects Prof. Varda Shalev to Board effective Sep 1, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Prof. Varda Shalev elected as independent director, effective Sep 1, 2023, until 2024 annual meeting.","Shalev is a healthcare executive, managing partner at Team8 Health VC, and professor at Tel Aviv University.","No arrangements or material interests with other parties; compensation same as other non-executive directors.","No family relationships with any director or executive officer of Teva."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288204,"accession_number":"0001157523-23-001212","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva Q2 2023 revenue $3.88B, GAAP loss $0.77/sh, non-GAAP EPS $0.56; raises revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.88B (+2% YoY, +4% local currency); AUSTEDO U.S. rev $308M.","GAAP net loss $863M ($0.77 loss per share) vs $232M loss in Q2 2022.","Non-GAAP diluted EPS $0.56, down from $0.68 YoY; non-GAAP operating margin 26.1%.","Free cash flow $632M; operating cash flow $324M.","FY 2023 revenue guidance raised to $15.0-$15.4B; all other guidance reaffirmed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.96,"consensus_revenue_estimate":null,"consensus_revenue_actual":7539000000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308659,"accession_number":"0001193125-23-167868","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2023-06-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Teva shareholders reject advisory vote on executive compensation at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected directors Sol J. Barer and Janet S. Vergis with ~490M and ~498M votes for, respectively.","Say-on-pay proposal failed: 319.2M for, 324.5M against, showing majority disapproval.","Auditor Kesselman & Kesselman (PwC) ratified with 712.7M votes for, 35.8M against.","Approximately 103.9M broker non-votes on director and say-on-pay items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308658,"accession_number":"0001193125-23-163060","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2023-06-08T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Teva concludes nationwide opioids settlement up to $4.25B; resolves all 50 states and >99% subdivisions","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Teva will pay up to $4.25B over 13 years, including $1.2B of generic Narcan (or $240M cash) to participating states and subdivisions.","Separate settlement with Nevada for $193M over 20 years, averting trial scheduled for August 2023.","Settlement becomes effective August 7, 2023; first payments expected in H2 2023, with Narcan shipments already begun.","Teva has now resolved opioid claims with all 50 U.S. states and more than 99% of litigating subdivisions and special districts.","Agreement includes no admission of wrongdoing; company avoids further litigation uncertainty."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308657,"accession_number":"0001193125-23-141992","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Teva director Jean-Michel Halfon resigns from board, effective May 8, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jean-Michel Halfon resigned immediately on May 8, 2023, citing personal reasons.","He served as a director since 2014, chairing the HR/Compensation and Compliance Committees.","Halfon was not standing for re-election at Teva's June 15, 2023 annual meeting; no disagreements with Teva."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308656,"accession_number":"0001157523-23-000797","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2023-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva Q1 revenue $3.7B flat YoY; non-GAAP EPS $0.40 down from $0.55; reaffirms FY 2023 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenues $3,661M flat YoY (up 4% local currency); GAAP loss per share ($0.18) improved from ($0.86).","Non-GAAP diluted EPS $0.40 vs $0.55 YoY; adjusted EBITDA $899M, down 21% from $1,135M.","Non-GAAP gross margin 49.1%, down from 54.2% due to inflationary pressures and unfavorable mix.","AUSTEDO grew 10% YoY and AJOVY grew 35% (local currency); UZEDY approved for schizophrenia.","Full-year 2023 outlook reaffirmed: revenue $14.8-15.4B, non-GAAP EPS $2.25-2.55, free cash flow $1.7-2.1B."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":3661000000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327435,"accession_number":"0001193125-23-066281","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Teva issues €1.3B and $1.1B senior notes at 7.375%-8.125% to fund $2.5B tender offer","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued €800M 7.375% '29 notes and €500M 7.875% '31 notes; plus $600M 7.875% '29 and $500M 8.125% '31 notes.","Net proceeds to fund tender offer for up to $2.5B (upsized from $2.25B) and repay outstanding debt.","Interest increases 0.10% per sustainability target not met starting Sep 2026.","Notes are senior unsecured, guaranteed by Teva; redeemable at make-whole or par near maturity.","Issuers: Teva Finance II (Euro) and Teva Finance III (USD)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327434,"accession_number":"0001193125-23-058966","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2023-03-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Teva prices $2.49B sustainability-linked senior notes; upsizes tender offer to $2.5B","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Priced €800M 7.375% notes due 2029, €500M 7.875% notes due 2031, $600M 7.875% notes due 2029, $500M 8.125% notes due 2031.","Upsized offering from $2.06B to $2.49B equivalent; increased tender offer max from $2.25B to $2.5B.","Proceeds to fund cash tender offers for six series of existing senior notes due 2023-2026 and repay debt.","Second sustainability-linked bond issuance; targets include improving medicine access in LMICs and reducing GHG emissions.","Settlement expected March 9, 2023; notes are unsecured senior obligations guaranteed by Teva."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327433,"accession_number":"0001157523-23-000205","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2023-02-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva reports FY2022 GAAP loss $2.12, non-GAAP EPS $2.52; Q4 rev $3.9B; guides 2023 lower","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2022 revenues $14.9B (-6% YoY); GAAP diluted loss per share $2.12; non-GAAP diluted EPS $2.52.","Q4 2022 revenues $3.9B; GAAP diluted loss per share $1.10; non-GAAP diluted EPS $0.71.","2023 guidance: revenues $14.8-15.4B, non-GAAP diluted EPS $2.25-2.55, free cash flow $1.7-2.1B.","Goodwill impairment charges of $2.045B and legal settlements of $2.082B recorded in 2022.","CEO Richard Francis noted AUSTEDO US sales +20% YoY, generics in Europe +9% local currency."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":14925000000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345152,"accession_number":"0001193125-22-289487","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2022-11-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Teva appoints Richard Francis as President and CEO effective Jan 1, 2023; Kåre Schultz to retire Dec 31, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Francis to receive $1.6M base salary, 150% target bonus, and $9M annual equity (70% PSU, 30% RSU).","Sign-on awards: $5M RSU (3-year vesting), $5M PSU (stretch goals), and $5M cash (3 installments).","Schultz to remain CEO through Dec 31, then on garden leave until Feb 19, 2023; treated as termination without cause.","Francis previously CEO of Sandoz (2014-2019) and senior exec at Biogen overseeing Tecfidera launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345151,"accession_number":"0001157523-22-001500","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva Q3 revenue falls 8% to $3.6B; non-GAAP EPS $0.59 flat; opioid settlement progress","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.595B (-8% YoY, -2% in local currency); GAAP EPS $0.05; non-GAAP EPS $0.59 (flat YoY).","2022 revenue guidance cut to $14.8-15.4B (prev $15.0-15.6B) due to FX; all other guidance affirmed.","Opioid litigation: substantial progress toward nationwide settlement; agreement in principle with NY AG; reserve updated.","AUSTEDO U.S. revenue +30% YoY, on track for ~$1B annual; AJOVY gains share in U.S., Europe, Japan.","Cash from operations $543M; free cash flow $685M; non-GAAP tax rate outlook revised to 12-14%."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":11041000000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361617,"accession_number":"0001157523-22-000904","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2022-07-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva Q2 revenue $3.8B, non-GAAP EPS $0.68; reaches $4.25B opioids settlement in principle","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.8B (-3% YoY, +1% local currency); GAAP loss $0.21, non-GAAP EPS $0.68 vs $0.59 prior year","Agreed in principle to nationwide opioids settlement: up to $4.25B + $100M for tribes over 13 years, includes Narcan supply","Revised 2022 revenue guidance to $15.0-$15.6B from $15.4-$16.0B due to FX; reaffirmed adjusted EBITDA, EPS, FCF","COPAXONE outlook lowered to ~$700M from ~$750M; non-GAAP tax rate outlook cut to 13%-14% from 18%-19%","Cash flow from ops $123M, free cash flow $301M; goodwill impairment and legal settlements drove GAAP loss"],"consensus_eps_estimate":null,"consensus_eps_actual":-1.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":7447000000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":380983,"accession_number":"0001193125-22-180042","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2022-06-23T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Teva shareholders approve amendments to Articles of Association and elect four directors at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendments to Articles, effective June 23, 2022, including eliminating minimum in-person board meetings and allowing chairman discretion on meetings in Israel.","Four directors elected: Amir Elstein, Roberto A. Mignone, Dr. Perry D. Nisen, Dr. Tal Zaks, each to serve until 2025 annual meeting.","Non-binding advisory vote on executive compensation approved with 424.6M for vs 137.8M against.","Appointment of Kesselman & Kesselman (PwC) as independent auditor approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":380982,"accession_number":"0001157523-22-000536","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2022-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva Q1 GAAP loss $0.86/share; revenue down 8%; cuts FY revenue guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted loss per share $0.86 vs. income $0.07 in Q1 2021; non-GAAP EPS $0.55 vs. $0.63.","Revenue $3.66B, down 8% YoY (5% local currency); FY 2022 revenue guidance lowered to $15.4-$16.0B.","GAAP operating loss $713M driven by $1.1B opioid litigation settlement provisions.","COPAXONE revenue outlook cut to ~$750M from ~$850M; adjusted EBITDA and EPS guidance reaffirmed.","First generic Revlimid launched in US; AJOVY and AUSTEDO growing; opioid settlements with Florida and Rhode Island."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":3661000000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399029,"accession_number":"0001193125-22-052050","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Teva EVP Global R&D Dr. Hafrun Fridriksdottir to depart, search underway","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Hafrun Fridriksdottir, EVP Global R&D, is leaving Teva.","She will remain in role until June 20, 2022 to assist transition.","Teva has initiated a search for the next head of Global R&D.","No successor has been named as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399028,"accession_number":"0001157523-22-000164","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2022-02-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva reports FY 2021 revenue down 5% to $15.9B; GAAP EPS $0.38; Q4 GAAP loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY 2021 revenues $15.9B, down 5% YoY; GAAP diluted EPS $0.38 vs -$3.64 in 2020.","Q4 2021 GAAP diluted EPS $(0.14); Non-GAAP diluted EPS $0.77.","FY 2021 non-GAAP diluted EPS $2.58 (flat YoY); free cash flow $2.2B.","2022 outlook: revenue $15.6-$16.2B, non-GAAP EPS $2.40-$2.60, FCF $1.9-$2.2B."],"consensus_eps_estimate":null,"consensus_eps_actual":0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":15878000000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418008,"accession_number":"0001193125-21-339389","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2021-11-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Teva appoints Amir Weiss as Chief Accounting Officer, replacing Andrew Weil","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrew Weil steps down as Chief Accounting Officer effective November 24, 2021.","Amir Weiss promoted from VP Finance and Corporate Controller to SVP and Chief Accounting Officer, effective same date.","Weiss's base salary increased to 840,000 NIS; eligible for 50% target annual cash incentive and equity awards.","Weiss joined Teva in 2012 and holds an MA in law, MBA, and CPA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418007,"accession_number":"0001193125-21-326070","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Teva issues €2.6B and $2B sustainability-linked notes; upsizes tender offer to $4B","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["€1.1B 3.750% notes due 2027 and €1.5B 4.375% notes due 2030 issued.","$1B 4.750% notes due 2027 and $1B 5.125% notes due 2029 issued.","Net proceeds used to fund tender offer for up to $4B (upsized from $3.5B) plus fees, debt repayment, and general purposes.","Interest rates may increase by up to 0.375% from May 2026 if sustainability targets not met.","Notes are senior unsecured obligations guaranteed by Teva; semi-annual interest begins May 9, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418006,"accession_number":"0001193125-21-320242","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Teva prices $5B equivalent sustainability-linked notes; proceeds to repay debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Teva upsized and priced €1.1B 3.75% notes due 2027, €1.5B 4.375% notes due 2030, $1B 4.75% notes due 2027, and $1B 5.125% notes due 2029.","Largest-ever sustainability-linked note offering and first by a generic medicine company; tied to access-to-medicines and GHG targets.","Net proceeds to fund tender offer for up to $3.5B of existing senior notes maturing 2022-2024 and for general corporate purposes.","Settlement expected November 9, 2021; notes are unsecured senior obligations guaranteed by Teva."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418005,"accession_number":"0001193125-21-316076","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2021-11-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Israeli court rules Teva owes ~$350M in back taxes for 2008-2011; Teva to appeal","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Israeli Central District Court ruled against Teva on tax assessments for 2008-2011, finding ~$350 million liability.","Teva had provided a reserve for a substantial portion in its Q3 2021 financial statements filed Oct 27, 2021.","Teva intends to appeal the ruling, asserting meritorious defenses; case for 2012-2016 remains pending.","Further adverse rulings in related or similar claims could be material to Teva's financials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418004,"accession_number":"0001157523-21-001258","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2021-10-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva Q3 revenues $3.9B (-2% YoY), non-GAAP EPS $0.59 vs $0.58; reaffirms FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.26 on net income $292M (vs loss $4.349B in Q3 2020).","Non-GAAP diluted EPS $0.59 on net income $651M (up from $0.58).","Free cash flow $795M; operating cash flow $529M.","FY 2021 outlook: revenue $16.0-16.4B, adj. EBITDA $4.8-5.1B, EPS $2.50-2.70, FCF $2.0-2.3B.","Announced collaboration with MODAG GmbH for movement disorder products; issued Sustainability-Linked Bond."],"consensus_eps_estimate":null,"consensus_eps_actual":0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":11778000000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":435584,"accession_number":"0001193125-21-258064","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2021-08-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Teva appoints Dr. Tal Zaks to Board of Directors, effective Oct 1, 2021","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Tal Zaks elected to Teva Board, effective Oct 1, 2021, until 2022 annual meeting.","Zaks joins from Moderna where he was Chief Medical Officer; departs late Sept 2021.","Determined independent under NYSE rules; appointed to Science and Technology Committee.","Will receive same compensation as other non-executive directors (see 2020 proxy).","Zaks has MD/PhD, experience at Sanofi, Cephalon, GSK, and as adjunct professor at UPenn and Tufts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":435583,"accession_number":"0001157523-21-000935","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2021-07-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Teva Q2 2021: Revenue $3.9B, GAAP EPS $0.19, Non-GAAP EPS $0.59; guides revenue lower","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $3.9B (up 1% YoY); GAAP diluted EPS $0.19 (vs $0.13 Q2 2020); Non-GAAP diluted EPS $0.59 (vs $0.55).","Net debt reduced by $500M to $22.7B; operating cash flow $218M, free cash flow $625M.","2021 revenue outlook cut to $16.0-16.4B (prior $16.4-16.8B) citing COVID impact; all other guidance reaffirmed: adj. EBITDA $4.8-5.1B, EPS $2.50-2.70, FCF $2.0-2.3B.","AUSTEDO sales grew YoY; AJOVY net sales $70M worldwide; Truxima US market share reached 25%.","R&D expenses $248M (GAAP), increased 10% YoY, driven by respiratory, biosimilar projects."],"consensus_eps_estimate":null,"consensus_eps_actual":0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":7892000000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":435582,"accession_number":"0001157523-21-000890","cik":818686,"company_name":"TEVA PHARMACEUTICAL INDUSTRIES LTD","ticker":"TEVA","form_type":"8-K","filed_at":"2021-07-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Teva announces executive reshuffle; North America Commercial head replaced, two promotions","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brendan O'Grady, EVP North America Commercial, resigns effective Aug 15, 2021 to pursue outside opportunity.","Sven Dethlefs appointed as new head of North America Commercial, from EVP Global Marketing and International Markets.","Mark Sabag moves to EVP International Markets Commercial; Galia Inbar becomes EVP Chief HR Officer.","Eli Shani promoted to EVP Global Marketing and Portfolio. All changes effective Aug 15, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":114658685710.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-07-21T23:59:59+00:00|435582"}